DS-1001b is a selective inhibitor of Fibroblast Growth Factor Receptor (FGFR), primarily utilized in medical research for the development of treatments for cancers with FGFR gene mutations. It targets the FGFR pathway, which is crucial for the survival and proliferation of cancer cells. By inhibiting this pathway, DS-1001b helps reduce tumor growth, metastasis, and cancer severity, while enhancing the effectiveness of other therapeutic agents. It is also being studied for its potential in overcoming drug resistance in cancer treatments, serving as a valuable component in combination therapies. Researchers are exploring its application in precision medicine, tailoring it to individual patient profiles for more effective and targeted outcomes. Ongoing clinical trials evaluate its efficacy and safety in treating various cancer types, with potential for future therapeutic development.